First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, Juliana Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Oscar Juan-Vidal, Aurelia Alexandru, Hiroshi Sakai, Alejo Lingua, Pamela Salman, Pierre-Jean Souquet, Pedro De Marchi, Claudio Martin, Maurice Pérol, Arnaud Scherpereel, Shun Lu, Thomas John, David P Carbone, Stephanie Meadows-Shropshire, Shruti Agrawal, Abderrahim Oukessou, Jinchun Yan, Martin Reck

Open source

DOI: 10.1016/s1470-2045(20)30641-0
Published: 2021-02
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-20-30641-0,
  title = {First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial},
  author = {Luis Paz-Ares and Tudor-Eliade Ciuleanu and Manuel Cobo and Michael Schenker and Bogdan Zurawski and Juliana Menezes and Eduardo Richardet and Jaafar Bennouna and Enriqueta Felip and Oscar Juan-Vidal and Aurelia Alexandru and Hiroshi Sakai and Alejo Lingua and Pamela Salman and Pierre-Jean Souquet and Pedro De Marchi and Claudio Martin and Maurice Pérol and Arnaud Scherpereel and Shun Lu and Thomas John and David P Carbone and Stephanie Meadows-Shropshire and Shruti Agrawal and Abderrahim Oukessou and Jinchun Yan and Martin Reck},
  year = {2021},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(20)30641-0},
  url = {https://doi.org/10.1016/s1470-2045(20)30641-0}
}

RIS

TY  - JOUR
TI  - First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
AU  - Luis Paz-Ares
AU  - Tudor-Eliade Ciuleanu
AU  - Manuel Cobo
AU  - Michael Schenker
AU  - Bogdan Zurawski
AU  - Juliana Menezes
AU  - Eduardo Richardet
AU  - Jaafar Bennouna
AU  - Enriqueta Felip
AU  - Oscar Juan-Vidal
AU  - Aurelia Alexandru
AU  - Hiroshi Sakai
AU  - Alejo Lingua
AU  - Pamela Salman
AU  - Pierre-Jean Souquet
AU  - Pedro De Marchi
AU  - Claudio Martin
AU  - Maurice Pérol
AU  - Arnaud Scherpereel
AU  - Shun Lu
AU  - Thomas John
AU  - David P Carbone
AU  - Stephanie Meadows-Shropshire
AU  - Shruti Agrawal
AU  - Abderrahim Oukessou
AU  - Jinchun Yan
AU  - Martin Reck
PY  - 2021
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(20)30641-0
UR  - https://doi.org/10.1016/s1470-2045(20)30641-0
ER  -

APA

Paz-Ares, L., Ciuleanu, T., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Salman, P., Souquet, P., Marchi, P. D., Martin, C., Pérol, M., Scherpereel, A., Lu, S., John, T., Carbone, D. P., Meadows-Shropshire, S., Agrawal, S., Oukessou, A., Yan, J., & Reck, M. (2021). First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30641-0

Source records

crossref · retrieved 2026-09-26T15:42:55.550Z